Abstract
Whenever sustained changes of activity and/or load occur all tissues of the body adapt their structural design. The hypertrophic response of skeletal muscle of athletes is an illustrative example of such an adaptative process. As a consequence of elevated arterial pressure, wall stress increases and, in an attempt to bring wall stress back to normal, the left ventricle adds contractile elements in parallel. Posterior and septal walls thicken and concentric left ventricular hypertrophy (LVH) [1] develops. Initially this increase in cardiac mass has little functional consequence; however, LVH cannot be simply considered a physiological adaptative process. In fact, it is known that, if elevated blood pressure is left untreated, the adaptative response ultimately fails, leading to heart failure. Furthermore, several epidemiological studies have demonstrated that LVH is one of the most powerful risk factors for heart attack, sudden death, and myocardial infarction [2-4]. These phenomena can be ascribed to abnormalities of myocardial structure and function associated with the development of LVH.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Messerli FH, Sungaard-Riise K, Reisin E, et al. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med 1983;99:757–761.
Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham Study. Ann Intern Med 1970;72:813–822.
Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986;105:173–178.
Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983;75(Supp1.3A):4–11.
Granger CB, Karimeddini MK, Smith VE, Shapiro MR, Katz AM, Riba AL. Rapid ventricular filling in left ventricular hypertrophy. I. Physiologic hypertrophy. J Am Coll Cardiol 1985;5:862–828.
Weber KT, Brilla CG, Janicki JS. Structural remodeling of myocardial collagen in systemic hypertension: Functional consequences and potential therapy. Heart failure 1990;6:129–137.
Weber KT, Janicki IS, Shroff SG, et al. Collagen compartment remodeling in the pressure overload left ventricle. J Appl Cardiol 1988,3:37–46.
Campbell DJ, Habener JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue, and mesentery: Quantification of messager ribonucleic acid abundance using hybridization in situ. Endrocrinology 1987;121:1616–1626.
Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelshon FAO. Localization of angiotensin converting enzime in the rat heart. Cir Res 1991; 68:141–149.
Johnston CI, Mooser V, Sun Y, Fabris B. Changes in cardiac angiotensin converting enzyme (ACE) after myocardial infartction and hypertrophy in rats. Cin Exp Pharmacol Physiol 1991;18:107–110.
Brilla CG, Zhou G, Weber KT. Aldosterone and collagen syntesis in cultured adult rat cardiac fibroblasts (Abstract). FASEB J 1992;6:A1914.
Zhou G, Brilla CG, Weber KT. Angiotensin II-mediated stimulation of collagen syntesis in cultured cardiac fibroblasts (Abstract). FASEB J 1992;6:A1914.
Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991;83: 1771–1779.
Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: Role of interstitial fibrosis and medial tickening of intramyocardial coronary arteries. Cir Res 1991;69:107–115.
De Luca N, Rosiello G, Lamenza F, et al. Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril. Am J Cardiol 1992;69:52–59D.
Strauer BE. Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol 1979;44:999–1006.
Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML. The effects of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Circulation 1988;77:1108–1115.
Polese A, DeCesare NF, Biochi MD, et al. Coronary autoregulation in hypertension. Correlation with left ventricular mass. J Am Coll Cardiol 1990;15:111A.
Pringle SD, Macfarlane, PW, McKillop JH, et al. Hypertensive left ventricular hypertrophy. Is there a high risk sub-group? J Am Coll Cardiol 1989;13:1277–1281.
Mark AL, Kerber RE: Augmentation of cardiopulmonary baroreflex control of forearm vascular resistance in borderline hypertension. Hypertension 1983;4:39–46.
Girerd X, Chanudet X, Clement R, Larroque P, London G, Safar M. Increased vasodilator response during stimulation of cardiopulmonary baroreceptors in borderline hypertensives (Abstract). 12th Sci Meet Int Soc Hypertens, Kyoto 1988:699.
Trimarco B, De Luca N, Ricciardelli B, et al. Impaired responsiveness of the ventricular sensory receptor in hypertensive patients with left ventricular hypertrophy. Circulation 1986;74:980–990.
Grassi G, Giannattasio C, Cléroux J, et al. Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension 1988;12:227–237.
Drayer JI, Gardin JM, Weber MA, Aronow WS. Changes in ventricular septal thickness during diuretic therapy. Clin Pharmacol Ther 1982;32:283–288.
Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa: Lack of association with blood pressure control. Am J Cardiol 1982;49:795–801.
Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrphy from systemic hypertension by enalapril. Am J Cardiol 1984;53:1044–1049.
Frohlich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cadiol 1979;44:959–968.
Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85–90.
Ferrario CM, Spech MM, Tarazi RC, Doy Y. Cardiac pumping ability in rats with experimental renal and genetic hypertension. Am J Cardiol 1979;44:979–985.
Betocchi S, Trimarco B. Cuocolo A, et al. Regression of concentric, but not eccentric left ventricular hypertrophy improves diastolic filling in patients with hypertension. Circulation 1987;76(Supp1.IV):440(A).
Trimarco B, De Luca N, De Simone A, et al. Impaired control of arginine vasopressin release by cardiopulmonary receptors in hypertensive patients with cardiac hypertrophy. Hypertension 1987;10:595–602.
Schulman S, Weiss J, Becker L, et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Eng J Med 1990;322:1350–1356.
Muiesau ML, Agabiti-Rosei E, Romanelli G, et al. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal and redevelopment of hypertension. J Cardiovas Pharmacol 1991;17(Suppl.2): 179–181.
Cuocolo A, Sax FL, Maron JE, et al. Left ventricular hypertrophy and impaired diastolic filling in essential hypertension. Diastolic mechanisms for systolic dysfunction during exercise. Circulation 1990;81:978–986.
Trimarco B, De Luca N, Ricciardelli B, et al. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol 1988;62:745–750.
Hoffinan JIE. A critical review on coronary reserve. Circulation 1987;75(Suppl.I): I-6–11.
Fleckenstein A. Specific inhibitors and promoters of calcium in the excitation-contraction coupling of heart muscle and their role in the prevention of myocardial lesions. In: Harris P, Opie L, editors. Calcium and heart. London: Academic Press, 1970:135–188.
Nayler WG. Second generation of calcium antogonists. Berlin: Springer Verlag, 1991b:136–152.
Grassi G, Giannattasio G, Saino A. Cardiopulmonary receptor modulation of plasma renin activity in normotensive and hypertensive subjects. Hypertension 1988; 11:92–99.
Perondi R. Saino A, Tio RA, et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 1992;85: 2004–2013.
Trimarco B, Lembo G, De Luca N, et al. Blunted sympathetic response to cardiopulmonary receptor in hypertensive patients with left ventricular hypertrophy possible involvement of atrial natriuretic factor. Circulation 1989;80:892–993.
Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989;80:65–77.
Ferguson DW, Hayes DW. Nifedipine potentiates cardiopulmonary baroreflex control of sympathetic nerve activity in healty humans. Direct evidence from neurographic studies. Circulation 1989;80:285–298.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Trimarco, B., Argenziano, L., Iovino, G.L., Sarno, D., Morisco, C. (1995). The Reversal of Hypertension-Induced Cardiac Damage by Antihypertensive Therapy with Calcium Antagonists. In: Godfraind, T., Mancia, G., Abbracchio, M.P., Aguilar-Bryan, L., Govoni, S. (eds) Pharmacological Control of Calcium and Potassium Homeostasis. Medical Science Symposia Series, vol 9. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0117-2_17
Download citation
DOI: https://doi.org/10.1007/978-94-011-0117-2_17
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4056-3
Online ISBN: 978-94-011-0117-2
eBook Packages: Springer Book Archive